Collaboration with Professor Philippe Menasché (PARCC Cardiovascular Research Center - Inserm - Université Paris Cité - UMR 970 and Cardiovascular Surgery Department, Georges Pompidou European Hospital)
Collaboration with Professor Philippe Menasché (PARCC Cardiovascular Research Center - Inserm - Université Paris Cité - UMR 970 and Cardiovascular Surgery Department, Georges Pompidou European Hospital)
This project will be conducted with the team entitled “Regenerative Therapies of Cardiac and Vascular Pathologies” directed by Dr. Jean-Sébastien Silvestre. The laboratory has scientific and technological expertise in the field of stem cells, extra-cellular vesicles, tissue engineering and myocardial ischemia-reperfusion animal models.
The goal of this collaboration, which follows an initial proof-of-concept phase, is to set up the animal model and evaluate the efficacy of a bioprinted biomaterial on a heart failure model in vivo in order to be on the verge of clinical trials within three to four years.
While the clinical indication selected as a priority is the treatment of heart failure*, the demonstration of the beneficial role of the co-developed patch (with an aim of cell and/or acellular therapy) could lead to an extension of the indications in several sectors of regenerative medicine, in particular those of skin healing, eye diseases and certain inflammatory intestinal diseases.
Professor Menasché underlines that “Heart failure is often the ultimate consequence of various cardiovascular diseases. The combination of Poietis’ technological expertise in bioprinting with ours in stem cell therapies, or the bioactive factors they produce, could lead relatively quickly to a new therapeutic strategy”.
Bruno Brisson, Business Development Director of Poietis, adds “We are very pleased to establish this new translational research collaboration with a leading international team in cardiac surgery and a pioneer in cell therapy for heart failure. This materializes the versatility of our bioprinting platform and the extension of its application portfolio”.
As a reminder, Poietis is a health technology company specialized in the development and manufacturing of human tissues by bioprinting. Operating its Next Generation Bioprinting platform compatible with Good Manufacturing Practices, its main mission is to develop new therapeutic solutions.
This collaboration contract was negotiated by Inserm Transfert, a private subsidiary of Inserm, on behalf of Inserm and Université Paris Cité.
*: In France, about 2.3% of the French population (i.e. 1.5 million people) has heart failure, which is responsible for 70,000 deaths per year (Santé Publique France 2019).
**********
About Poietis: Poietis is a health technology company specialized in the development and manufacturing of human tissues by bioprinting. Its main mission is to develop new therapeutic solutions based on its expertise in bioprinting technologies and in particular in high resolution laser bioprinting. Poietis has developed the Next Generation Bioprinting (NGB) platform, which is available in a research version for tissue bioengineering (NGB-R) and a clinical grade version (NGB-C) compatible with Good Manufacturing Practices for ATMPs and implantable bioprinted tissue production. This multimodal, robotic platform allows for the fabrication of complex tissues while ensuring repeatability and reproducibility. Poietis’ bioprinting technology is the result of innovative research conducted for over ten years at Inserm and the University of Bordeaux. Founded in September 2014, Poietis operates a portfolio of over 70 patents and currently employs 32 people.
Contacts:
Bruno Brisson, co-founder; Dir. Business Development - Tel: +33535544728 - bruno.brisson@poietis.com
